Thymosin α1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria

Journal of Infectious Diseases

Volumn 198, Issue 5, 2008, Pages 723-730

  Zhang, Ying ^a   Chen, Hao ^a   Li, Yu Min ^b   Zheng, Shu Sen ^a   Chen, Ya Gang ^a   Li, Lan Juan ^a   Zhou, Lin ^a   Xie, Hai Yang ^a   Praseedom, Raaj Kumar ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CYTOKINE; IMIPENEM; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MEROPENEM; PLACEBO; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; DRUG DERIVATIVE; GLYCOPROTEIN; IMMUNOLOGIC FACTOR; THYMOSIN;

ABDOMINAL INFECTION; ADULT; ANTIBIOTIC RESISTANCE; APACHE; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLASGOW COMA SCALE; HUMAN; IMMUNOMODULATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; SURVIVAL; AGED; BACTERIUM; CHOLANGITIS; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; INTESTINE OBSTRUCTION; LIVER ABSCESS; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PANCREATITIS; PERITONITIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIA; CARBAPENEMS; CHOLANGITIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOLOGIC FACTORS; INTESTINAL OBSTRUCTION; LIVER ABSCESS; MALE; MIDDLE AGED; PANCREATITIS; PERITONITIS; SEPSIS; THYMOSIN;

EID: 50949088722     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/590500     Document Type: Article

References (16)

1. Singh S, Evans TW. Organ dysfunction during sepsis. Intensive Care Med 2006; 32:349-60.
2. Goldstein AL, Guha A, Zatz MM, Hardy MA, White A. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci U S A 1972; 69:1800-3.
3. Jönsson-Berling BM, Ohlsson K, Rosengren M. Radioimmunological quantitation of the urinary trypsin inhibitor in normal blood and urine. Biol Chem Hoppe Seyler 1989; 370:1157-61.
4. Inoue K, Takano H, Shimada A, et al. Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Mol Pharmacol 2005; 67:673-80.
5. Andrews P, Azoulay E, Antonelli M, et al. Year in Review in Intensive Care Medicine, 2006. III. Circulation, ethics, cancer, outcome, education, nutrition, and pediatric and neonatal critical care. Intensive Care Med 2007; 33:414-22.
6. Bumroongkit C, Liwsrisakun C, Deesomchok A, Theerakittikul T, Pothirat C. Efficacy of weaning protocol in medical intensive care unit of tertiary care center. J Med Assoc Thai 2005; 88:52-7.
7. Bone RC, Balk RA, Cerra FB, et al. Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest 1992; 101:1644-55.
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 16th informational supplement, M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
9. Osvaldt AB, Viero P, Borges da Costa MS, Wendt LR, Bersch VP, Rohde L. Evaluation of Ranson, Glasgow, APACHE-II, and APACHE-O criteria to predict severity in acute biliary pancreatitis. Int Surg 2001; 86:158-61.
10. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score are reliable descriptor of a complex outcome. Crit Care Med 1995; 23:1638-52.
11. Hudak AM, Caesar RR, Frol AB, et al. Functional outcome scales in traumatic brain injury: a comparison of the Glasgow Outcome Scale (Extended) and the Functional Status Examination. J Neurotrauma 2005; 22:1319-26.
12. National Center for Health Statistics. National Vital Statistics Reports, table E: deaths and percentages of total deaths for the ten leading causes of death, by race: United States, 2001. Atlanta, GA: National Center for Health Statistics, 2003:9
13. Knutsen AP, Freeman JJ, Mueller KR, Roodman ST, Bouhasin JD. Thymosin-α stimulates maturation of CD34+ stem cells into CD3+4+cells in an in vitro thymic epithelia organ coculture model. Int J Immunopharmacol 1999; 21:15-26.
14. Bochkov VN, Kadl A, Huber J, Gruber F, Binder BR, Leitinger N. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 2002; 419:77-81.
15. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor- and potentiates interleukin-10 production during human endotoxemia. J Clin Invest 1996; 97:713-9.
16. The Cooperative Group of Immunomodulatory Therapy of Sepsis, Lin HY. Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with ulinastatin and Maipuxin. Zhonghua Yi Xue Za Zhi 2007; 87:451-7.